Related Experiment Video
Updated: Jun 25, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Depression: Managing Resistance and Partial Response to Treatment
Heidi L Gaddey1, Brandyn Mason1, Amol Naik1
1Carle Foundation Hospital Family Medicine Residency, Urbana, Illinois.
Treatment-resistant depression (TRD) affects many patients despite multiple medication trials. Management involves psychotherapy, medication adjustments, or novel treatments like ketamine, electroconvulsive therapy, and transcranial magnetic stimulation.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Treatment-resistant depression (TRD) is a significant clinical challenge, affecting up to 31% of individuals with major depressive disorder.
- TRD is characterized by a lack of remission despite adequate trials of at least two antidepressant medications.
- Partial response, defined as less than 50% symptom reduction, necessitates careful adherence confirmation before diagnosing TRD.
Purpose of the Study:
- To outline current management strategies for treatment-resistant depression (TRD).
- To review pharmacologic and non-pharmacologic interventions for TRD.
- To discuss the role of newer treatments and the limitations of pharmacogenetic testing.
Main Methods:
- Review of current clinical guidelines and evidence for TRD management.
- Identification of augmentation strategies including pharmacologic and non-pharmacologic options.
- Evaluation of emerging treatments such as ketamine, esketamine, electroconvulsive therapy (ECT), and repetitive transcranial magnetic stimulation (rTMS).
Main Results:
- Augmentation with second-generation antidepressants, atypical antipsychotics, tricyclic antidepressants, lithium, or triiodothyronine are recommended pharmacologic options.
- Ketamine and esketamine show potential for TRD and reducing suicidal ideation.
- Electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) are effective non-pharmacologic interventions.
- Pharmacogenetic testing currently lacks sufficient evidence for routine clinical recommendation.
Conclusions:
- Effective management of TRD involves a multimodal approach, including psychotherapy, medication class switching, and augmentation.
- Novel pharmacologic agents (ketamine, esketamine) and neuromodulation techniques (ECT, rTMS) offer promising alternatives for refractory depression.
- Confirmation of medication adherence and dose is critical prior to implementing advanced TRD strategies.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: MAOIs and Other Agents
Drug Therapy
Antianxiety Medications
Electroconvulsive Therapy
Mania and Antimanic Drugs: Overview
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...

